Russell L Morris

This inventor holds 28 USPTO granted patents and 6 published patent applications, plus 1 CIPO patent and 5 EPO patents, primarily in Transdermal Drug Delivery. Top assignees: Teikoku Pharma USA, Inc., Birch Point Medical, Inc., Travanti Pharma Inc.. Active years: 2002-2026.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Russell L Morris. Retrieved from https://idiyas.com/inventor/russell-l-morris

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

Calculating rank

USPTO Granted Patents = 28 (Patent Applications = 6)

% Patents Active = 50.0

CIPO Patents = 1

EPO Patents = 5 (Patent Applications = 2)

Average Co-Inventor Count = 2.4

ph-index = 10

Forward Citations = 404(Granted Patents)

Company Filing History:

9 out of 52

Teikoku Pharma USA, Inc.

patents

6 out of 6

Birch Point Medical, Inc.

Verde Environmental Technologies, Inc.

Teva Pharmaceuticals International Gmbh

patents

7. 1 out of 1

Vail Scientific, Inc.

patent

Years Active: 2002-2026

Loading Chart...

Areas of Expertise:

Transdermal Systems

Iontophoresis

Abuse Potential Reduction

Therapeutic Agents

Dosage Control

Medication Disposal

Endothelial Dysfunction

Sepsis Risk

Corticosteroid Delivery

Anti-Migraine Compounds

Sacrificial Electrode Design

Controlled Dosage

28 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 12539073 - Apparatus and method for the determination of endothelial dysfunction and sepsis risk using nitric oxide concentrations in exhaled breath (2026-02-03),

2. 11305144 - Abuse potential reduction in abusable substance dosage form (2022-04-19),

3. 10413768 - Abuse potential reduction in abusable substance dosage form (2019-09-17),

4. 10406394 - Abuse potential reduction in abusable substance dosage form (2019-09-10),

5. 10391346 - Abuse potential reduction in abusable substance dosage form (2019-08-27),

6. 9764130 - Transdermal systems for the delivery of therapeutic agents including granisetron using iontophoresis (2017-09-19),

7. 9421356 - Transdermal methods and systems for the delivery of corticosteroid compounds (2016-08-23),

8. 9272137 - Transdermal methods and systems for the delivery of anti-migraine compounds (2016-03-01),

9. 8535711 - Medication disposal system (2013-09-17),

10. 8475837 - Abuse potential reduction in abusable substance dosage form (2013-07-02),

11. 8470853 - Transdermal methods and systems for the delivery of anti-migraine compounds (2013-06-25),

12. 8463373 - Transdermal systems for the delivery of therapeutic agents including granisetron using iontophoresis (2013-06-11),

13. 8445010 - Abuse potential reduction in abusable substance dosage form (2013-05-21),

14. 8329212 - Abuse potential reduction in abusable substance dosage form (2012-12-11),

15. 8295924 - Transdermal systems for the delivery of ionic agents directly to open wounds and surgically repaired incisions (2012-10-23),

Title: **Inventor Spotlight: Russell L. Morris**

Introduction

Russell L. Morris is an innovative inventor based in Lindstrom, Minnesota, known for his significant contributions to the field of pharmaceuticals. With an impressive portfolio of 27 patents, Morris has devoted his career to reducing the potential for substance abuse through innovative dosage forms.

Latest Patents

Among his latest innovations is the patent titled "Abuse potential reduction in abusable substance dosage form." This invention addresses the concerns surrounding the residual amounts of abusable substances that remain in used skin-worn patches. Morris provides a system and method that combines the abusable substance with an anti-abuse substance agent, specifically designed for use during the removal or disposal procedure of these patches. This innovative approach significantly minimizes the risk of abuse associated with these substances.

Career Highlights

Russell L. Morris has made substantial impacts during his time with notable companies such as Teikoku Pharma USA, Inc. and Birch Point Medical, Inc. His role in these organizations has been pivotal in the development of safer pharmaceutical products that cater to the needs of patients while addressing public health concerns regarding substance abuse.

Collaborations

Throughout his career, Morris has collaborated with esteemed professionals, including Carter R. Anderson and Robert Cohen. These partnerships have enriched his work, allowing for the exchange of ideas and fostering innovation in the pharmaceutical domain.

Conclusion

In summary, Russell L. Morris stands out as a passionate inventor committed to enhancing safety in drug delivery systems. His groundbreaking patents not only reflect his dedication to innovation but also illustrate his proactive approach to tackling issues related to substance abuse. As he continues to innovate, the impact of his work is expected to resonate within the pharmaceutical industry for years to come.

Profile summary based on public USPTO records.